CytomX Therapeutics, Inc. announced the promotion of Amy C. Peterson, M.D., to the position of president and chief operating officer, effective immediately. Dr. Peterson has served as the company's executive vice president and chief development officer since October 2019 and will continue to report to Sean McCarthy, D. Phil., chief executive officer and chairman of CytomX. Prior to joining CytomX, Dr. Peterson was chief medical officer of immuno-oncology at BeiGene Ltd. where she created and led a global oncology development organization with direct medical oversight and accountability of seven clinical assets across more than 30 global trials in all phases of development in solid tumor indications.

Previous to that role, Dr. Peterson was vice president of clinical development at Medivation where she was primarily responsible for the development of enzalutamide (XTANDI®) and talazoparib (TALZENNA®) in breast cancer. Dr. Peterson also served as associate group medical director at Genentech, where she oversaw the development of early-stage molecules targeting multiple major pathways in oncology. Prior to her time at Genentech, Dr. Peterson was an instructor of medicine in Oncology at the University of Chicago, where she conducted translational research in tumor immunology in conjunction with Dr. Thomas F. Gajewski.

Dr. Peterson currently serves on the board of Conquer Cancer®, the ASCO Foundation. Dr. Peterson received her M.D. from Thomas Jefferson University and completed her residency in internal medicine at Northwestern Memorial Hospital and fellowship in hematology and oncology at the University of Chicago.